RAPT THERAPEUTICS, INC.
561 Eccles Avenue
South San Francisco, California 94080
August 15, 2023
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
RAPT Therapeutics, Inc.
Registration Statement on Form S-3
Filed August 11, 2023
File No. 333-273910
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the Registrant) hereby requests that the Securities and Exchange Commission (the Commission) take appropriate action to cause the Registration Statement on Form S-3 (File No. 333-273910) (the Registration Statement) to become effective on Thursday, August 17, 2023, at 4:00 p.m., Eastern Time, or as soon as practicable thereafter, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission (the Staff). The Registrant hereby authorizes Courtney Tygesson of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Courtney Tygesson of Cooley LLP, counsel to the Registrant, at (312)881-6680, or in her absence Christina Roupas of Cooley LLP at (312) 881-6670.
Very truly yours,
|RAPT THERAPEUTICS, INC.|
|By:||/s/ Brian Wong|
|Title:||President and Chief Executive Officer|
Michael Listgarten, General Counsel, RAPT Therapeutics, Inc.
Courtney Tygesson, Cooley LLP
Christina Roupas, Cooley LLP